Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (PSTV) has secured a $17.6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance Rhenium-186 NanoLiposome (186RNL) aimed at treating leptomeningeal metastases. This funding will cover a significant portion of the developmental costs for the next three years. Additionally, the clinical trial for 186RNL continues to progress with Cohort 1 enrollment completed, demonstrating no dose-limiting toxicities. The therapy has received FDA Fast Track designation, indicating significant potential in addressing this severe cancer complication.
Plus Therapeutics, Inc. (PSTV) announced a share repurchase program authorized for up to $2.0 million of its outstanding common stock, signaling strong confidence in its long-term strategy and balance sheet. The program will be funded through available cash and executed based on market conditions over the next 12 months. The company intends to utilize Rule 10b5-1 trading plans for buybacks, while maintaining flexibility to adjust the program as needed. This initiative underlines Plus Therapeutics' commitment to enhancing shareholder value.
Plus Therapeutics (PSTV) showcased positive findings from ongoing trials of Rhenium-186 Nanoliposome (186RNL) for treating recurrent glioblastoma (GBM) and leptomeningeal metastases at the 2022 CNS Clinical Trials Conference. The Phase 1/2a trial reported safe administration of 186RNL, demonstrating a substantial decrease in cerebrospinal fluid (CSF) cell count in treated patients. Additionally, significant overall survival benefits were noted in GBM patients receiving high radiation doses. The company aims to continue clinical evaluations and further dose escalations.
Plus Therapeutics (PSTV) announced the presentation of data from two clinical trials targeting recurrent glioblastoma and leptomeningeal metastases at the 2022 CNS Clinical Trials and Brain Metastases Conference on August 12-13, 2022. The oral presentation will focus on the safety and feasibility of Rhenium-186 Nanoliposome in leptomeningeal metastases, while a poster will cover its use in recurrent glioma as part of the ReSPECT Phase 1 Trial. This showcases advancements in innovative, targeted radiotherapeutics for challenging cancer types.
Plus Therapeutics (PSTV) announced that Dr. Norman LaFrance will present on their investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), at the Targeted Radiopharmaceuticals Summit in Boston on July 27, 2022. The presentation is titled ‘Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers’, and will provide updates on the U.S. ReSPECT clinical trials. Plus Therapeutics focuses on developing innovative cancer therapies, utilizing advanced nanotechnology for drug delivery.
Plus Therapeutics (PSTV) announced the completion of Cohort 1 enrollment in the ReSPECT-LM Phase 1/2a trial for 186RNL, targeting leptomeningeal metastases. The company achieved key manufacturing objectives and presented positive interim data on 186RNL for glioblastoma. Financially, cash stood at $18.1 million with a net loss of $5.3 million for Q2 2022. Operating expenses rose to $5.1 million due to CMC development costs. The company plans multiple data presentations and aims to finalize GMP production for ongoing clinical trials by the end of 2022.
Plus Therapeutics, Inc. (PSTV) announced it will report its second quarter 2022 financial results on July 21, 2022, post-market. Following this, management will host a conference call at 5:00 p.m. ET to discuss results and provide corporate updates. A live webcast will be available, and participants can pre-register for the call. Plus Therapeutics focuses on innovative, targeted radiotherapeutics for tough cancers, employing proprietary nanotechnology for enhanced drug delivery.
Plus Therapeutics (PSTV) has successfully completed technology transfer and initiated cGMP manufacturing of its Rhenium-186 NanoLiposome (186RNL) drug intermediate with Piramal Pharma Solutions. This milestone supports ongoing clinical trials for rare cancers. The 186RNL product is currently undergoing stability testing and adheres to FDA guidelines. The company is on track to provide GMP drug availability in late 2022 for trials focusing on recurrent glioblastoma and leptomeningeal metastases. Feedback from recent FDA meetings will guide future clinical development plans.
Plus Therapeutics (PSTV) has entered a multi-year agreement with Biocept to utilize the CNSide assay in its ReSPECT-LM clinical trial, aiming to treat patients with leptomeningeal metastasis. This assay will help monitor tumor cell burden in cerebrospinal fluid (CSF) and evaluate treatment response, enhancing the effectiveness of Rhenium-186 NanoLiposome (186RNL). CNSide offers advanced detection and quantification of tumor cells, significantly benefiting the clinical trial's patient management and treatment assessment.
Plus Therapeutics (PSTV) announced the successful completion of enrollment for the first cohort in its ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) targeting leptomeningeal metastases. Initial results show no dose limiting toxicities, indicating promising drug performance. The next step involves the Data Safety & Monitoring Board evaluating further dose escalation. The investigational drug aims to provide a safer, effective treatment for this rare cancer complication, which has a dismal survival rate. Plus Therapeutics expects to release further updates in Q3 2022.